中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
9期
783-785
,共3页
质子泵抑制剂%幽门螺杆菌%消化性溃疡%成本-效果分析
質子泵抑製劑%幽門螺桿菌%消化性潰瘍%成本-效果分析
질자빙억제제%유문라간균%소화성궤양%성본-효과분석
Proton pump inhibitor%Helicobacter pylori%Peptic ulcer%Cost-effectiveness analysis
目的：对根除幽门螺杆菌（Hp）的三联治疗方案中的3种质子泵抑制剂进行药物经济学评价，为临床用药提供参考。方法：选择2012年9月至2013年9月Hp阳性的消化性溃疡患者106例随机分成3组，A组给予奥美拉唑+奥硝唑+克拉霉素，B组给予雷贝拉唑+奥硝唑+克拉霉素，C组给予艾普拉唑+奥硝唑+克拉霉素，疗程均为10 d。停药4周后运用成本-效果分析方法进行经济学评价。结果：3组治疗方案的总有效率分别为88.57％、91.43％、91.57％，组间差异无统计学意义（P＞0.05）；成本-效果比分别为2.59、2.51、8.88。结论：从药物经济学角度，奥美拉唑和雷贝拉唑的三联疗法成本-效果相当，优于艾普拉唑三联疗法。
目的：對根除幽門螺桿菌（Hp）的三聯治療方案中的3種質子泵抑製劑進行藥物經濟學評價，為臨床用藥提供參攷。方法：選擇2012年9月至2013年9月Hp暘性的消化性潰瘍患者106例隨機分成3組，A組給予奧美拉唑+奧硝唑+剋拉黴素，B組給予雷貝拉唑+奧硝唑+剋拉黴素，C組給予艾普拉唑+奧硝唑+剋拉黴素，療程均為10 d。停藥4週後運用成本-效果分析方法進行經濟學評價。結果：3組治療方案的總有效率分彆為88.57％、91.43％、91.57％，組間差異無統計學意義（P＞0.05）；成本-效果比分彆為2.59、2.51、8.88。結論：從藥物經濟學角度，奧美拉唑和雷貝拉唑的三聯療法成本-效果相噹，優于艾普拉唑三聯療法。
목적：대근제유문라간균（Hp）적삼련치료방안중적3충질자빙억제제진행약물경제학평개，위림상용약제공삼고。방법：선택2012년9월지2013년9월Hp양성적소화성궤양환자106례수궤분성3조，A조급여오미랍서+오초서+극랍매소，B조급여뢰패랍서+오초서+극랍매소，C조급여애보랍서+오초서+극랍매소，료정균위10 d。정약4주후운용성본-효과분석방법진행경제학평개。결과：3조치료방안적총유효솔분별위88.57％、91.43％、91.57％，조간차이무통계학의의（P＞0.05）；성본-효과비분별위2.59、2.51、8.88。결론：종약물경제학각도，오미랍서화뢰패랍서적삼련요법성본-효과상당，우우애보랍서삼련요법。
OBJECTIVE:To conduct pharmacoeconomic evaluation on proton pump inhibitors in three triple therapies for Heli-cobacter pylori(Hp)eradication for clinical reference of drug use. METHODS:Between September 2012 and September 2013,a to-tal of 106 peptic ulcer patients with Hp positive were randomly assigned to receive omeprazole plus ornidazole and clarithromycin (group A),rabeprazole plus ornidazole and clarithromycin (group B) or ilaprazole plus ornidazole and clarithromycin (group C) for 10 days. After drug withdrawal for 4 weeks,a cost-effectiveness analysis was performed for economic evaluation. RESULTS:The total effective rates of the three groups were 88.57%,91.43%and 91.57%respectively,showing no statistically significant dif-ferences between groups (P>0.05);the cost-effectiveness ratios in the three groups were 2.59,2.51 and 8.88 respectively. CON-CLUSIONS:From the perspective of pharmacoeconomics,the triple therapy with omeprazole is as cost-effective as the triple thera-py with rabeprazole but better than the triple therapy with ilaprazole.
